medvisМедицинская визуализацияMedical Visualization1607-07632408-9516RDS-Media Ltd.10.24835/1607-0763-2020-2-144-152medvis-921Research ArticleНОВЫЕ ТЕХНОЛОГИИ ЛУЧЕВЫХ ИССЛЕДОВАНИЙNEW TECHNOLOGIES IN RADIOLOGYБиохимические основы визуализации при позитронной эмиссионной томографии в онкологии. Часть 3Biochemical basics of imaging in positron emission tomography in oncology. Part 3https://orcid.org/0000-0002-6345-9500ЛеонтьевА. В.LeontyevA. V.

Леонтьев Алексей Викторович – канд. мед. наук, заведующий отделением радионуклидной диагностики

125284 Москва, 2-й Боткинский пр., д. 3

Alexey V. Leontyev – Cand. of Sci. (Med.), Head of Nuclear Medicine Department 

3, 2nd Botkinsky pr.; Moscow 125284

aleksleont@yandex.ruhttps://orcid.org/0000-0001-8378-4338РубцоваН. А.RubtsovaN. A.

Рубцова Наталья Алефтиновна – доктор мед. наук, руководитель отдела лучевой диагностики

125284 Москва, 2-й Боткинский пр., д. 3

Natalia A. Rubtsova – Doct. of Sci. (Med.), Head of Radiology Department 

3, 2nd Botkinsky pr.; Moscow 125284

rna17@yandex.ruhttps://orcid.org/0000-0002-8905-4202ХалимонА. И.KhalimonA. I.

Халимон Александр Игоревич – врач-рентгенолог отделения КТ и МРТ

125284 Москва, 2-й Боткинский пр., д. 3

Alexander I. Khalimon – radiologist of CT and MRI Department 

3, 2nd Botkinsky pr.; Moscow 125284

markyhaws@gmail.comhttps://orcid.org/0000-0002-4864-0643ХамадееваГ. Ф.KhamadeevaG. F.

Хамадеева Гульнара Фаридовна – клинический ординатор отделения радионуклидной диагностики

125284 Москва, 2-й Боткинский пр., д. 3

Gulnara F. Khamadeeva – Resident of Nuclear Medicine Department 

3, 2nd Botkinsky pr.; Moscow 125284

g.hamadeeva@yandex.ruhttps://orcid.org/0000-0002-3508-1782КулиевМ. Т.KulievM. T.

Кулиев Магомед Темирланович – клинический ординатор кафедры онкологии, радиотерапии и пластической хирургии лечебного факультета ФГАОУ ВО Первый МГМУ имени И.М. Сеченова (Сеченовский Университет) на базе отделения радионуклидной диагностики

125284 Москва, 2-й Боткинский пр., д. 3

Magomed T. Kuliev – Resident of Oncology, Radiotherapy and Plastic Surgery Department of Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) based at the Nuclear Medicine Department 

3, 2nd Botkinsky pr.; Moscow 125284

kul502@yandex.ruhttps://orcid.org/0000-0002-1280-620XПыловаИ. В.PylovaI. V.

Пылова Ирина Валентиновна – канд. мед. наук, врач-радиолог отделения радионуклидной диагностики

125284 Москва, 2-й Боткинский пр., д. 3

Irina V. Pylova – Cand. of Sci. (Med.), nuclear medicine physician of Nuclear Medicine Department 

3, 2nd Botkinsky pr.; Moscow 125284

irinapylova@mail.ruhttps://orcid.org/0000-0002-7835-4939ЛазутинаТ. Н.LazutinaT. N.

Лазутина Татьяна Николаевна – канд. мед. наук, врач-радиолог отделения радионуклидной диагностики 

125284 Москва, 2-й Боткинский пр., д. 3

Tatyana N. Lazutina – Cand. of Sci. (Med.), nuclear medicine physician of Nuclear Medicine Department

3, 2nd Botkinsky pr.; Moscow 125284

t.n.lazutina@yandex.ruhttps://orcid.org/0000-0002-0792-6012КостинА. А.KostinA. A.

Костин Андрей Александрович – доктор мед. наук, профессор, первый заместитель генерального директора ФГБУ "НМИЦ радиологии" Минздрава России; заведующий кафедрой урологии, онкологии, радиологии факультета повышения квалификации медицинских работников медицинского института ФГАОУ ВО "Российский университет дружбы народов"

125284 Москва, 2-й Боткинский пр., д. 3

Andrey A. Kostin – Doct. of Sci. (Med.), Professor, First Deputy of General director of “National Medical Research Center of Radiology” of the Ministry of Healthcare of Russia, Head of Urological, oncological and radiological department of Faculty of advanced training of medical workers of medical institute of The Peoples' Friendship University of Russia

3, 2nd Botkinsky pr.; Moscow 125284

andocrey@mail.ruhttps://orcid.org/0000-0001-8784-8415КапринА. Д.KaprinA. D.

Каприн Андрей Дмитриевич – академик РАН, член-корр. РАО, доктор мед. наук, профессор, главный уролог РАН, заслуженный врач РФ, генеральный директор ФГБУ “ НМИЦ радиологии” Минздрава России; заведующий кафедрой урологии и оперативной нефрологии с курсом онкоурологии медицинского факультета медицинского института ФГАОУ ВО “Российский университет дружбы народов”

125284 Москва, 2-й Боткинский пр., д. 3

kaprin@mail.ruМНИОИ имени П.А. Герцена – филиал ФГБУ “Национальный медицинский исследовательский центр радиологии” Минздрава РоссииРоссияP.A. Herzen Moscow Research Oncology Institute – branch of “National Medical Research Center of Radiology” of the Ministry of Healthcare of RussiaRussian Federation202018062020242Медицинская визуализация 2020№2144152Copyright © Леонтьев А.В., Рубцова Н.А., Халимон А.И., Хамадеева Г.Ф., Кулиев М.Т., Пылова И.В., Лазутина Т.Н., Костин А.А., Каприн А.Д., 20202020Леонтьев А.В., Рубцова Н.А., Халимон А.И., Хамадеева Г.Ф., Кулиев М.Т., Пылова И.В., Лазутина Т.Н., Костин А.А., Каприн А.Д.Leontyev A.V., Rubtsova N.A., Khalimon A.I., Khamadeeva G.F., Kuliev M.T., Pylova I.V., Lazutina T.N., Kostin A.A., Kaprin A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medvis.rdsmedia.ru/jour/article/view/921

Настоящая статья содержит обзор основных литературных данных, посвященных биохимическим основам и клиническому применению позитронной эмиссионной томографии – одной из перспективных технологий лучевой визуализации в онкологии. В заключительной части подробно рассмотрены особенности биокинетики радиофармацевтических препаратов, отражающих пролиферативную активность злокачественных клеток и степень гипоксии в опухолевом очаге. Представлены результаты исследований, посвященных оценке их эффективности, основные показания к их применению, особенности подготовки к исследованию, а также перспективные научные разработки в данной отрасли.

This article provides an overview of the main literature data of biochemical basics and the clinical application of positron emission tomography, one of the promising technologies of radiation imaging in oncology.

In the final part, the biokinetics of radiopharmaceuticals that display the proliferative activity of malignant cells and the degree of hypoxia in the tumor focus are examined in detail. The results of studies devoted to assessing their effectiveness, the main indications for their use, the features of preparation for the study, as well as promising scientific developments in this industry are presented.

ПЭТ/КТрадиофармпрепаратыФЛТFMAUтимидингипоксияFMISOFAZAHX4ATSMPET/CTradiopharmaceuticalsFLTFMAUhypoxiaFMISOFAZAHX4ATSMReferencesShields A.F., Grierson J.R., Dohmen B.M., Machulla H.J., Stayanoff J.C., Lawhorn-Crews J.M., Obradovich J.E., Muzik O., Mangner T.J. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 1998; 4: 1334–1336. http://doi.org/10.1038/3337Shields A.F., Grierson J.R., Dohmen B.M., Machulla H.J., Stayanoff J.C., Lawhorn-Crews J.M., Obradovich J.E., Muzik O., Mangner T.J. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 1998; 4: 1334–1336. http://doi.org/10.1038/3337Barwick T., Bencherif B., Mountz J.M., Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nuclear Med. Communications. 2009; 30 (12): 908–917. http://doi.org/10.1097/MNM.0b013e32832ee93bBarwick T., Bencherif B., Mountz J.M., Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nuclear Med. Communications. 2009; 30 (12): 908–917. http://doi.org/10.1097/MNM.0b013e32832ee93bJensen M.M., Kjaer A. Monitoring of anti-cancer treatment with 18F-FDG and 18F-FLT PET: a comprehensive review of pre-clinical studies. Am. J. Nucl. Med. Mol. Imaging. 2015; 5 (5): 431–456.Jensen M.M., Kjaer A. Monitoring of anti-cancer treatment with 18F-FDG and 18F-FLT PET: a comprehensive review of pre-clinical studies. Am. J. Nucl. Med. Mol. Imaging. 2015; 5 (5): 431–456.Belt J.A., Marina N.M., Phelps D.A., Crawford C.R. Nucleoside transport in normal and neoplastic cells. Adv. Enzyme Regul. 1993; 33: 235–252.Belt J.A., Marina N.M., Phelps D.A., Crawford C.R. Nucleoside transport in normal and neoplastic cells. Adv. Enzyme Regul. 1993; 33: 235–252.Fanti S., Farsad M., Mansi L. PET-CT Beyond FDG. A Quick Guide to Image Interpretation. Berlin; Heidelberg: Springer-Verlag, 2010.Fanti S., Farsad M., Mansi L. PET-CT Beyond FDG. A Quick Guide to Image Interpretation. Berlin; Heidelberg: Springer-Verlag, 2010.Pauleit D., Floeth F., Herzog H., Hamacher K., Tellmann L., Muller H.W., Coenen H.H., Langen K.-J. Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-ltyrosine. Eur. J. Nucl. Med. Mol. Imaging. 2003; 30: 519– 524. http://doi.org/10.1007/s00259-003-1118-0Pauleit D., Floeth F., Herzog H., Hamacher K., Tellmann L., Muller H.W., Coenen H.H., Langen K.-J. Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-ltyrosine. Eur. J. Nucl. Med. Mol. Imaging. 2003; 30: 519– 524. http://doi.org/10.1007/s00259-003-1118-0Buck A.K., Hermann K., Shen C., Dechow T., Schwaiger M., Wester H.J. Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine. Methods. 2009; 48 (2): 205–215. http://doi.org/10.1016/j.ymeth.2009.03.009Buck A.K., Hermann K., Shen C., Dechow T., Schwaiger M., Wester H.J. Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine. Methods. 2009; 48 (2): 205–215. http://doi.org/10.1016/j.ymeth.2009.03.009Soloviev D., Lewis D., Honess D., Aboagye E. [(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur. J. Cancer. 2012; 48: 416–424. http://doi.org/10.1016/j.ejca.2011.11.035Soloviev D., Lewis D., Honess D., Aboagye E. [(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur. J. Cancer. 2012; 48: 416–424. http://doi.org/10.1016/j.ejca.2011.11.035Barwick T., Bencherif B., Mountz J.M., Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18-fluoro-L-thymidine: a comprehensive evaluation. Nucl. Med. Communications. 2009; 30: 908–917. http://doi.org/10.1097/MNM.0b013e32832ee93bBarwick T., Bencherif B., Mountz J.M., Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18-fluoro-L-thymidine: a comprehensive evaluation. Nucl. Med. Communications. 2009; 30: 908–917. http://doi.org/10.1097/MNM.0b013e32832ee93bJensen M.M., Kjaer A. Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies. Am. J. Nucl. Med. Mol. Imaging. 2015; 5 (5): 431–456.Jensen M.M., Kjaer A. Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies. Am. J. Nucl. Med. Mol. Imaging. 2015; 5 (5): 431–456.Miyake K., Shinomiya A., Okada M., Hatakeyama T., Kawai N., Tamiya T. Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas. J. Biomed. Biotechnol. 2012. 205818. http://doi.org/10.1155/2012/205818Miyake K., Shinomiya A., Okada M., Hatakeyama T., Kawai N., Tamiya T. Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas. J. Biomed. Biotechnol. 2012. 205818. http://doi.org/10.1155/2012/205818Glaudemans A.W., Enting R.H., Heesters M.A., Dierckx R.A., van Rheenen R.W., Walenkamp A M., Slart R.H. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur. J. Nucl. Med. Mol. Imaging. 2012. http://doi.org/10.1007/s00259-012-2295-5Glaudemans A.W., Enting R.H., Heesters M.A., Dierckx R.A., van Rheenen R.W., Walenkamp A M., Slart R.H. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur. J. Nucl. Med. Mol. Imaging. 2012. http://doi.org/10.1007/s00259-012-2295-5Alauddin M.M. Journey of 2'-deoxy-2'-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU): from Antiviral Drug to PET Imaging Agent. Curr. Med. Chem. 2018; 25 (16): 1867–1878. http://doi.org/10.2174/0929867325666171129125217Alauddin M.M. Journey of 2'-deoxy-2'-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU): from Antiviral Drug to PET Imaging Agent. Curr. Med. Chem. 2018; 25 (16): 1867–1878. http://doi.org/10.2174/0929867325666171129125217Sun H., Sloan A., Mangner T.J., Vaishampayan U., Muzik O., Collins J.M., Douglas K., Shields A.F. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur. J. Nucl. Med. Mol. Imaging. 2005; 32 (1): 15–22.Sun H., Sloan A., Mangner T.J., Vaishampayan U., Muzik O., Collins J.M., Douglas K., Shields A.F. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur. J. Nucl. Med. Mol. Imaging. 2005; 32 (1): 15–22.Jadvar H., Chen K., Ukimura O. Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET/CT. Clin. Nucl. Med. 2015; 40 (8): e426– e428. http://doi.org/10.1097/rlu.0000000000000814Jadvar H., Chen K., Ukimura O. Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET/CT. Clin. Nucl. Med. 2015; 40 (8): e426– e428. http://doi.org/10.1097/rlu.0000000000000814Varghese B., Velez E., Desai B., Jadvar H. Incidental Detection of Meningioma by 18F-FMAU PET/CT in a Patient With Suspected Prostate Cancer. Clin. Nucl. Med. 2018; 43 (7): e245–e246. http://doi.org/10.1097/RLU.0000000000002123Varghese B., Velez E., Desai B., Jadvar H. Incidental Detection of Meningioma by 18F-FMAU PET/CT in a Patient With Suspected Prostate Cancer. Clin. Nucl. Med. 2018; 43 (7): e245–e246. http://doi.org/10.1097/RLU.0000000000002123Клиническое исследование “ПЭТ/КТ с 18F-FMAU в диагностике и характеристике рака предстательной железы”. Доступно по: https://clinicaltrials.gov/ct2/showNCT02809690 Ссылка активна на 06.09.2019г.Clinical trial “18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer”. Available at: https:/clinicaltrials.gov/ct2/show/NCT02809690 (In Russian)Semenza G.L., Jiang B.H., Leung S.W. et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 1996; 271 (51): 32529–32537. http://doi.org/10.1074/jbc.271.51.32529Semenza G.L., Jiang B.H., Leung S.W. et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 1996; 271 (51): 32529–32537. http://doi.org/10.1074/jbc.271.51.32529Semenza G.L., Roth P.H., Fang H.M., Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 1994; 269 (38): 23757–23763.Semenza G.L., Roth P.H., Fang H.M., Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 1994; 269 (38): 23757–23763.Lopci E., Grassi I., Chiti A., Nanni C., Cicoria G., Toschi L., Fonti C., Lodi F., Mattioli S., Fanti S. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am. J. Nucl. Med. Mol. Imaging. 2014; 4 (4): 365–384.Lopci E., Grassi I., Chiti A., Nanni C., Cicoria G., Toschi L., Fonti C., Lodi F., Mattioli S., Fanti S. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am. J. Nucl. Med. Mol. Imaging. 2014; 4 (4): 365–384.Li F., Jørgensen J.T., Madsen J., Kjaer A. Pharmacokinetic analysis of 64Cu-ATSM dynamic PET in human xenograft tumors in mice. Diagnostics. 2015; 5 (2): 96– 112. http://doi.org/10.3390/diagnostics5020096Li F., Jørgensen J.T., Madsen J., Kjaer A. Pharmacokinetic analysis of 64Cu-ATSM dynamic PET in human xenograft tumors in mice. Diagnostics. 2015; 5 (2): 96– 112. http://doi.org/10.3390/diagnostics5020096Thorwarth D., Wack L.-J., Mönnich D. Hypoxia PET imaging techniques: data acquisition and analysis. Clin. Transl. Imaging. 2017; 5: 489–496. https://doi.org/10.1007/s40336-017-0250-yThorwarth D., Wack L.-J., Mönnich D. Hypoxia PET imaging techniques: data acquisition and analysis. Clin. Transl. Imaging. 2017; 5: 489–496. https://doi.org/10.1007/s40336-017-0250-yChen L., Zhang Z., Kolb H.C., Walsh J.C., Zhang J., Guan Y. 18F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with 18F-FMISO. Nucl. Med. Commun. 2012; 33 (10): 1096–1102. https://doi.org/10.1097/MNM.0b013e3283571016Chen L., Zhang Z., Kolb H.C., Walsh J.C., Zhang J., Guan Y. 18F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with 18F-FMISO. Nucl. Med. Commun. 2012; 33 (10): 1096–1102. https://doi.org/10.1097/MNM.0b013e3283571016Shaughnessy F., Mariotti E., Shaw K.P., Eykyn T.R., Blower P.J., Siow R., Southworth R. Modification of intracellular glutathione status does not change the cardiac trapping of 64Cu (ATSM). EJNMMI Research. 2014; 4: 40. https://doi.org/10.1186/s13550-014-0040-8Shaughnessy F., Mariotti E., Shaw K.P., Eykyn T.R., Blower P.J., Siow R., Southworth R. Modification of intracellular glutathione status does not change the cardiac trapping of 64Cu (ATSM). EJNMMI Research. 2014; 4: 40. https://doi.org/10.1186/s13550-014-0040-8Mortensen L.S., Johansen J., Kallehauge J., Primdahl H., Busk M., Lassen P., Alsner J., Sorensen B.S., Toustrup K., Jakobsen S., Petersen J., Petersen H., Theil J., Nordsmark M., Overgaard J. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012; 105: 14–20. https://doi.org/10.1016/j.radonc.2012.09.015Mortensen L.S., Johansen J., Kallehauge J., Primdahl H., Busk M., Lassen P., Alsner J., Sorensen B.S., Toustrup K., Jakobsen S., Petersen J., Petersen H., Theil J., Nordsmark M., Overgaard J. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012; 105: 14–20. https://doi.org/10.1016/j.radonc.2012.09.015Kikuchi M., Yamane T., Shinohara S., Fujiwara K., Hori S.Y., Tona Y., Yamazaki H., Naito Y., Senda M. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann. Nucl. Med. 2011; 25 (9): 625–633. https://doi.org/10.1007/s12149-011-0508-9Kikuchi M., Yamane T., Shinohara S., Fujiwara K., Hori S.Y., Tona Y., Yamazaki H., Naito Y., Senda M. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann. Nucl. Med. 2011; 25 (9): 625–633. https://doi.org/10.1007/s12149-011-0508-9Tateichi K., Tateishi U., Sato M., Yamanaka S., Kanno H., Murata H., Inoue T., Kawahara N. Application of 62Cudiacetyl-bis(N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxiainducible factor-1a expression in patients with glioma. Am. J. Neuroradiol. 2013; 34: 92–99. https://doi.org/10.3174/ajnr.A3159Tateichi K., Tateishi U., Sato M., Yamanaka S., Kanno H., Murata H., Inoue T., Kawahara N. Application of 62Cudiacetyl-bis(N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxiainducible factor-1a expression in patients with glioma. Am. J. Neuroradiol. 2013; 34: 92–99. https://doi.org/10.3174/ajnr.A3159Grosu A.L., Souvatzoglou M., Roper B., Dobritz M., Wieden mann N., Jacob V., Wester H.J., Reischl G., Machulla H.J., Schwaiger M., Molls M., Piert M. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007; 69: 541–551.Grosu A.L., Souvatzoglou M., Roper B., Dobritz M., Wieden mann N., Jacob V., Wester H.J., Reischl G., Machulla H.J., Schwaiger M., Molls M., Piert M. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007; 69: 541–551.Melsens E., De Vlieghere E., Descamps B., Vanhove C., Kersemans K., De Vos F., Goethals I., Brans B., De Wever O., Ceelen W., Pattyn P. Hypoxia imaging with 18F-FAZA PETCT predicts radiotherapy response in esophageal adenocarcinoma xenografts. Radiat. Oncol. 2018; 13 (1): 39. https://doi.org/10.1186/s13014-018-0984-3Melsens E., De Vlieghere E., Descamps B., Vanhove C., Kersemans K., De Vos F., Goethals I., Brans B., De Wever O., Ceelen W., Pattyn P. Hypoxia imaging with 18F-FAZA PETCT predicts radiotherapy response in esophageal adenocarcinoma xenografts. Radiat. Oncol. 2018; 13 (1): 39. https://doi.org/10.1186/s13014-018-0984-3

The authors declare that there are no conflicts of interest present.